The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
Abstract
Aberrant signaling by transforming growth factor-β (TGF-β) and its type I (ALK5) receptor has been implicated in a number of human diseases and this pathway is considered a potential target for therapeutic intervention. Transforming growth factor-β signaling via ALK5 plays a critical role during heart development, but the role of ALK5 in the adult heart is poorly understood. In the current study, the preclinical toxicology of ALK5 inhibitors from two different chemistry scaffolds was explored. Ten-week-old female Han Wistar rats received test compounds by the oral route for three to seven days. Both compounds induced histopathologic heart valve lesions characterized by hemorrhage, inflammation, degeneration, and proliferation of valvular interstitial cells. The pathology was observed in all animals, at all doses tested, and occurred in all four heart valves. Immunohistochemical analysis of ALK5 in rat hearts revealed expression in the valves, but not in the myocardium. Compared to control animals, protein levels of ALK5 were unchanged in the heart valves of treated animals. We also observed a physeal dysplasia in the femoro-tibial joint of rats treated with ALK5 inhibitors, a finding consistent with a pharmacological effect described previously with ALK5 inhibitors. Overall, these findings suggest that TGF-β signaling via ALK5 plays a critical role in maintaining heart valve integrity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Initial dose escalation studies of galunisertib or other TβRI kinase inhibitors mandated monitoring for cardiotoxicity due to heart valve dysplasia that was observed in rats and dogs receiving high doses of drug340,341.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [341]
Citations
Cites
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,860
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,923
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Sanford, L. P., Ormsby, I., Groot, A. C. G.-D., Sariola, H., Friedman, R., Boivin, G. P., Cardell, E. L., & Doetschman, T. (1997) · Development · doi:10.1242/dev.124.13.2659 · Cited by 1,447
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1926 · Cited by 1,291
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 882
Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β)
Roberts, A. B., & Sporn, M. B. (1993) · Growth Factors · doi:10.3109/08977199309029129 · Cited by 755
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 714
Verrecchia, F., & Mauviel, A. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.01641.x · Cited by 683
Research works printed but not linked: 3
- Hauck A. J., 1990, Arch Pathol Lab Med, 114, 62
- Mulholland D. L., 1996, Can J Cardiol, 12, 231
- Ten Dijke P., 1993, Oncogene, 8, 2879
Cited by
Sorted by citations
Transforming Growth Factor-β Signaling in Immunity and Cancer
Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Du, B., & Shim, J. S. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 829
Metadata
- Authors
- Anderton, M. J., Mellor, H. R., Bell, A., Sadler, C., Pass, M., Powell, S., Steele, S. J., Roberts, R. R. A., & Heier, A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Heier, Annabelle
- Venue
- Toxicologic Pathology
- Publisher
- SAGE Publications
- Published
- 2011-08-22
- Volume
- 39
- Issue
- 6
- Pages
- 916-924
- ISSN
- 0192-6233 (ISSN-L)
- 1533-1601
- OpenAlex
- W2140740750
- Cited by
- 284
- References
- 55
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 33 · 2023: 20 · 2022: 27 · 2021: 33 · 2020: 30 · 2019: 20 · 2018: 16 · 2017: 13 · 2016: 17 · 2015: 12 · 2014: 12 · 2013: 8 · 2012: 8
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Toxicologic Pathology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Keywords
- ALK5 inhibitor, heart valve lesions, TGF-beta signaling, valvular interstitial cells, cardiotoxicity, preclinical toxicology, femorotibial joint, small molecule inhibitors
- MeSH terms
- Receptor, Transforming Growth Factor-beta Type I, Administration, Oral, Animals, Drug Evaluation, Preclinical, Female, Heart Valves, Immunohistochemistry, Signal Transduction, Transforming Growth Factor beta, Rats, Wistar, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, Protein Kinase Inhibitors, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
